Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca137 Merck Sharp & Dohme LLC98 Hoffmann-La Roche81 Novartis Pharmaceuticals72 Janssen Research & Development, LLC71
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in London

2015 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Birmingham, London, Glasgow, Cardiff, Manchester
2027-11-23
Not yet open
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT07032038Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Rinri Therapeutics
Phase 1/2
20
Birmingham, Cambridge, London
2027-09
Not yet open
Transdermal Delivery Solutions Corp
Phase 2
48
London
2027-06
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
London, Leeds, Sheffield
2027-02-03
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
NCT07815574Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
DrugsImmunoBody·Yervoy·Ipilimumab·Opdivo
Scancell Ltd
Phase 3
550
London
2026-12-01
Not yet open
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Not yet open
Novo Nordisk A/S
Phase 3
84
Birmingham, Cardiff, London, Oxford, Sheffield
2026-10-09
Not yet open
Chiesi Farmaceutici S.p.A.
Phase 1
120
Leeds, London, Manchester
2026-10-01
Not yet open
Tangram Therapeutics Plc
Phase 1
40
London
2026-10
Recruiting
Yaqrit Ltd
Not applicable
72
London
2026-10
Not yet open
Assembly Biosciences
Phase 2
80
London, Manchester
2026-10
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
Aberdeen, Cardiff, Glasgow, Leeds, London
2026-09-30
Recruiting
Zedsen Limited
Observational
220
London
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham
2026-09-29
Recruiting
Boehringer Ingelheim
Phase 3
466
Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford
2026-09-17
Recruiting
CSL Behring
Phase 3
63
London, Leicester
2026-09-15
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
London, Southampton, Leicester, Newcastle upon Tyne
2026-09-11
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
London, Coventry
2026-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
160
Birmingham, London, Guildford
2026-09-10
Recruiting
Takeda
Phase 3
324
Lincoln, Leicester, London, Sunderland, Birmingham
2026-09-10
Recruiting
RyCarma Therapeutics, Inc.
Phase 2
28
Oswestry, London
2026-09-09
Recruiting
Sanofi
Phase 2
8,000
Cardiff, Bournemouth, Dorchester, London, Portsmouth, Blackpool, Witney, West Kirby
2026-09-09
Recruiting
JCR Pharmaceuticals Co., Ltd.
Phase 1/2
12
London
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
AstraZeneca
Phase 3
2,800
Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea
2026-09-01
Recruiting
AusperBio Therapeutics Inc.
Phase 2
70
London
2026-09-01
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Not yet open
Essilor International
Not applicable
96
London
2026-09
Not yet open
Eli Lilly and Company
Phase 3
170
Hull, Liverpool, London
2026-09
Not yet open
Eisai Limited
Observational
400
Edinburgh, London, Motherwell
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington
2026-08-31
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
London, Sheffield
2026-08-31
Recruiting
AstraZeneca
Phase 3
1,072
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
2026-08-31
Recruiting
Intuitive Surgical
Phase 4
550
London
2026-08-28
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
2026-08-28
Recruiting
Kardigan, Inc.
Phase 3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-08-26
Not yet open
AstraZeneca
Phase 3
750
Cambridge, London
2026-08-25
Recruiting
35Pharma Inc
Phase 1/2
90
London
2026-08-19
Recruiting
VarmX B.V.
Phase 3
800
Gloucester, London
2026-08-18
Recruiting
Hoffmann-La Roche
Phase 3
100
London, Sheffield
2026-08-18
Recruiting
Genespire Srl
Observational
30
London, Manchester
2026-08-13
Recruiting
AstraZeneca
Phase 3
600
Coventry, Knutsford, London, Orpington, Poole, Shipley
2026-08-12
Recruiting
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
Eli Lilly and Company
Phase 2
606
Cheadle, Ely, Hounslow, London, Penzance, West Kirby
2026-08-07
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Not yet open
EBI Anti Sepsis BV
Phase 3
300
London
2026-08-01
Recruiting
VectivBio AG
Phase 3
124
London, Aberdeen, Birmingham, Salford
2026-08
Not yet open
Entrada Therapeutics, Inc.
Phase 2
80
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2026-08
Recruiting
Boehringer Ingelheim
Phase 3
448
Bristol, Leeds, London, Salford
2026-07-27
Recruiting
GlaxoSmithKline
Phase 3
800
London, Sheffield
2026-07-27
Recruiting
Cochlear
Not applicable
20
London, Nottingham, Sheffield
2026-07-24
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
London
2026-07-24
Recruiting
Boehringer Ingelheim
Phase 3
35
Birmingham, London
2026-07-21
Recruiting
Sensory Cloud, Inc.
Phase 2
60
Belfast, London
2026-07-13
Recruiting
Clinical Investigation of the Performance of Epinamel for Dental White Spot Lesions
NCT07730359White Spot Lesions [Initial Caries] on Smooth Surface of Tooth
Mintech Bio Ltd
Not applicable
20
London
2026-07-06
Not yet open
Genie Fertility Ltd
Observational
100
London
2026-07-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
272
London, Liverpool
2026-07-01
Not yet open
GE Healthcare
Not applicable
50
London
2026-07
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
Liverpool, London, Manchester
2026-06-30
Recruiting
Hoffmann-La Roche
Phase 1
25
Liverpool, London, Newcastle upon Tyne
2026-06-29
Recruiting
A-TANGO Phase 2 Study
NCT06890039Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic
DrugsFilgrastim·G-Csf
Yaqrit Ltd
Phase 2
78
London
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Edinburgh, London, Manchester
2026-06-26
Recruiting
Gold Standard Phantoms
Observational
66
London
2026-06-26
Recruiting
First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration
NCT07269665Bardet-Biedl Syndrome 1, Retinal Degeneration
Axovia Therapeutics
Early Phase 1
12
London
2026-06-26
Recruiting
Novartis Pharmaceuticals
Phase 2
60
London
2026-06-26
Recruiting
ViiV Healthcare
Phase 3
564
Birmingham, Liverpool, London
2026-06-25
Recruiting
GlaxoSmithKline
Phase 1/2
64
Manchester, London
2026-06-22
Recruiting
GlaxoSmithKline
Phase 3
450
London
2026-06-18
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bristol, Cottingham, Edinburgh, Exeter, Liverpool, London
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
London
2026-06-11
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
London, Manchester
2026-06-05
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
London, Newcastle upon Tyne
2026-06-05
Recruiting
GlaxoSmithKline
Phase 3
600
Sutton, Leicester, London
2026-06-04
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
London, Manchester
2026-06-04
Recruiting
AstraZeneca
Phase 1/2
152
Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
2026-06-03
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Bristol, Liverpool, London, Nottingham
2026-06-02
Recruiting
Myota GmbH
Not applicable
120
London
2026-06-01
Not yet open
Traws Pharma, Inc.
Phase 2
165
London
2026-06
Recruiting
Pfizer
Phase 2
24
London, Bristol, Liverpool, Sheffield
2026-05-28
Recruiting
Janssen Research & Development, LLC
Phase 3
644
London
2026-05-23
Recruiting
Kite, A Gilead Company
Phase 3
550
Cardiff, London, Newcastle upon Tyne
2026-05-22
Recruiting
Revolution Medicines, Inc.
Phase 3
670
London
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Leicester, Liverpool, London, Manchester, Montacute
2026-05-21
Recruiting
Takeda
Phase 3
300
Leicester, Boston, Oxford, Birmingham, London, Manchester
2026-05-21
Recruiting
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
Recruiting
Lumos Pharma
Phase 3
150
Liverpool, London, Sheffield
2026-05-20
Recruiting
Novartis Pharmaceuticals
Phase 1
24
London
2026-05-19
Recruiting
Takeda
Phase 2
222
Cornhill, Luton, Glasgow, London
2026-05-17
Recruiting
Hoffmann-La Roche
Phase 3
138
London, Cardiff, Oxford
2026-05-15
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
London, Salford
2026-05-14
Recruiting
Ipsen
Phase 3
350
Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow
2026-05-14
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
30
Birmingham, London, Salford
2026-05-13
Recruiting
Genmab
Phase 2
160
London
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Dorchester, London, Preston, Harrow, Rochdale, Portadown, Taunton, Chertsey
2026-05-11
Recruiting
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
NCT07613723Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
DrugsFludarabine·Cyclophosphamide
Zelluna Immunotherapy AS
Phase 1
9
London, Manchester
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
London, Nottingham, Oxford
2026-05-11
Recruiting
Hoffmann-La Roche
Phase 3
8
London
2026-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
London, Birmingham, Leicester
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Aberdeen, Manchester, London
2026-05-06
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Bath, London
2026-05-06
Recruiting
AstraZeneca
Phase 2
24
Cambridge, London, Manchester
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
London, Middlesbrough, Southampton, Truro
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
London, Swansea
2026-05-04
Recruiting
Altesa Biosciences, Inc.
Phase 2
180
Bromborough, Glasgow, London, Milton Keynes, Wolverhampton
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
Portal Therapeutics, Inc.
Observational
50
Cardiff, Dundee, London, Manchester
2026-04-30
Recruiting
Hoffmann-La Roche
Phase 3
360
London, Cardiff
2026-04-27
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Bath, London, Plymouth, Sheffield
2026-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Cambridge, London
2026-04-23
Recruiting
Inhibikase Therapeutics
Phase 3
486
Cambridge, Glasgow, London
2026-04-23
Recruiting
BioNTech SE
Phase 3
736
Cambridge, London, Sutton
2026-04-22
Recruiting
Synendos Therapeutics AG
Phase 2
24
London
2026-04-22
Recruiting
Tessera Therapeutics, Inc.
Phase 1/2
72
London, Nottingham
2026-04-21
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Greater London, Iselworth, London, Norwich, Wolverhampton
2026-04-21
Recruiting
Richmond Research Institute
Observational
100
London
2026-04-21
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
Bristol, Glasgow, Liverpool, London, Manchester
2026-04-20
Recruiting
Boehringer Ingelheim
Phase 2
405
Basingstoke, Belfast, Cambridge, Doncaster, London
2026-04-20
By invitation
BioMarin Pharmaceutical
Phase 2
18
London
2026-04-20
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182Juvenile Idiopathic Arthritis (JIA)
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
London
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
Mediar Therapeutics
Phase 2
85
Coventry, Liverpool, London, Westcliff-on-Sea
2026-04-16
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
DrugSonlicromanol
Khondrion BV
Phase 3
220
London
2026-04-14
Recruiting
Eli Lilly and Company
Phase 2
60
London, Salford
2026-04-14
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Edinburgh, London
2026-03-31
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
AstraZeneca
Phase 2
43
London, Manchester
2026-03-28
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Leicester, Liverpool, London
2026-03-27
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 1
48
London
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 3
325
Exeter, London, Oxford, Chertsey, Sheffield, Crowborough, Motherwell
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
London
2026-03-25
Recruiting
JCR Pharmaceuticals Co., Ltd.
Observational
57
Belfast, Birmingham, London, Manchester, Salford
2026-03-25
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Cambridge, Bury, London, Huddersfield
2026-03-24
Recruiting
Boehringer Ingelheim
Phase 2
132
Bradford, London, Salford
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Glasgow, London, Manchester
2026-03-23
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab
CatalYm GmbH
Phase 2
104
Edinburgh, London
2026-03-19
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Salford, Glasgow, Brighton, London, Wrexham
2026-03-19
Recruiting
Santen SAS
Observational
112
London
2026-03-19
Recruiting
Quoin Pharmaceuticals
Phase 2/3
16
London, Walsall
2026-03-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
London, Portsmouth
2026-03-18
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
AstraZeneca
Phase 1/2
180
Cambridge, London, Sutton
2026-03-17
Recruiting
AIRNA Corporation
Phase 1
54
Cambridge, London, Southampton
2026-03-17
Recruiting
Sanofi
Observational
60
Birmingham, London
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
London, Glasgow, Metropolitan Borough of Wirral
2026-03-16
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
London, Oxford, Sutton, Glasgow, Manchester
2026-03-13
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
London
2026-03-12
Recruiting
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Hemab ApS
Phase 2
18
London
2026-03-11
Recruiting
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Torquay, Birmingham, Cambridge, Liverpool, London, Manchester
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Cambridge, Glasgow, London, Sheffield, Swindon
2026-03-03
Recruiting
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
NCT07427680Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc
Phase 1/2
99
London
2026-03-03
Recruiting
Alnylam Pharmaceuticals
Phase 1
44
London
2026-03-02
Not yet open
Axon Therapies, Inc.
Not applicable
50
Leeds, London
2026-03-01
Active, closed
Bristol-Myers Squibb
Observational
300
London
2026-02-28
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Cottingham, Cardiff, London, Manchester
2026-02-26
Recruiting
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
London
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Cambridge, Cottingham, Ipswich, London, Maidstone, Sutton
2026-02-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Cambridge, Leicester, London, Manchester
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Carshalton, Leicester, London, Middlesbrough, Salford
2026-02-16
Recruiting
Neurocrine Biosciences
Phase 2
120
London, Oxford
2026-02-16
Recruiting
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
Kardigan, Inc.
Phase 2/3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-02-13
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
24
Leeds, London
2026-02-11
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
Exeter, London
2026-02-10
Recruiting
Promedius Inc
Observational
595
Westcliff-on-Sea, London
2026-02-10
Recruiting
AstraZeneca
Phase 2
124
Brighton, Guildford, Liverpool, London
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Not yet open
The Concert Therapy for Stress Regulation in a Non-Clinical Adult Population
NCT07430631Stress Regulation and Well-being in Non-clinical Contexts
Behnam Khodarahmi
Not applicable
150
London
2026-02-09
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
55
London
2026-02-09
Recruiting
RIG 101 Trial in Healthy Adults and Adults With Asthma
NCT07488897Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
RIGImmune Inc.
Phase 1/2
82
London, Manchester
2026-02-09
Recruiting
Chong Kun Dang Pharmaceutical
Phase 1
519
London
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
SYSNAV
Observational
140
London
2026-02-06
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
NCT07155850Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable
BetaGlue Therapeutics SpA
Not applicable
10
London
2026-02-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
London
2026-02-03
Recruiting
AstraZeneca
Phase 3
2,130
Cambridge, Dundee, Leeds, London, Manchester, Oxford
2026-02-03
Recruiting
CSL Behring
Phase 2
63
London
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Birmingham, Edgbaston, Trumpington, Exeter, Oxford, Edinburgh, London
2026-02-02
Recruiting
Prilenia
Phase 3
500
London, Stoke-on-Trent
2026-02-01
Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 2/3
28
London, Manchester
2026-01-30
Recruiting
Denali Therapeutics Inc.
Phase 1
68
London
2026-01-30
Active, closed
Glyconics Ltd
Not applicable
100
Ashton-under-Lyne, London
2026-01-28
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Active, closed
Hoffmann-La Roche
Phase 1
6
London, Southampton, Glasgow
2026-01-27
Recruiting
IDEAYA Biosciences
Phase 3
520
Metropolitan Borough of Wirral, London, Sheffield
2026-01-25
Recruiting
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Liverpool, London, Manchester, Sheffield
2026-01-22
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
City Therapeutics
Phase 1
182
London
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
High Wycombe, Ashburton, Bristol, London, Romford, Rotherham, Thetford, Nottingham
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Edinburgh, Truro, London, Withington
2026-01-19
Recruiting
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Active, closed
EveryONE Medicines Inc.
Phase 1/2
1
London
2026-01-13
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
London
2026-01-13
Active, closed
Kailera
Phase 3
1,270
Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Edinburgh, London
2026-01-09
Recruiting
Novo Nordisk A/S
Phase 3
460
Birmingham, Liverpool, London
2026-01-08
Recruiting
Amicus Therapeutics
Phase 3
8
London, Manchester
2026-01-08
Recruiting
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Belfast, Glasgow, Salford, Southampton
2026-01-07
By invitation
Medtronic
Observational
2,000
Liverpool, London, Southampton
2026-01-07
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
Sheffield, Glasgow, London
2026-01-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Leicester, London
2026-01-02
Recruiting
Theradex
Phase 2
66
London, Manchester
2026-01-01
Active, closed
Kailera
Phase 3
1,270
Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham
2025-12-30
Recruiting
Complement Therapeutics
Phase 1/2
75
Gloucester, London, Sunderland
2025-12-30
Recruiting
Incyte Corporation
Phase 2
56
Cottingham, London, Plymouth
2025-12-29
Recruiting
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Active, closed
UCB Biopharma SRL
Phase 2
165
London, Salford
2025-12-29
Recruiting
Galmed Pharmaceuticals Ltd
Phase 1
32
London
2025-12-25
Recruiting
nChroma Bio
Phase 1/2
66
London
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
800
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
2025-12-22
Recruiting
Javier Toledo
Observational
6,000
Cambridge, London
2025-12-20
Recruiting
Vector Y Therapeutics
Phase 1/2
12
London, Sheffield
2025-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
London
2025-12-19
Recruiting
argenx
Phase 2
60
Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds
2025-12-19
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
London, Manchester
2025-12-17
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
780
Belfast, Bristol, Dagenham, London, Maidstone, Manchester, Orpington, Portsmouth
2025-12-17
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Chester, Eastbourne, Glasgow, London, Nottingham, Oxford
2025-12-16
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Birmingham, Glasgow, Liverpool, London, Manchester
2025-12-15
Recruiting
Novartis Pharmaceuticals
Observational
3,000
London
2025-12-15
Recruiting
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
NCT07072468Chemotherapy-induced Peripheral Neuropathy, Drug-Induced Nephropathy
VM Therapeutics LLC
Phase 2
16
London
2025-12-12
Recruiting
Alnylam Pharmaceuticals
Phase 1
76
London
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Huddersfield, London, Manchester, Sheffield
2025-12-12
Recruiting
Angitia Incorporated Limited
Phase 2
80
Cambridge, Edinburgh, London, Oxford
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Cardiff, London, Manchester, Sheffield
2025-12-11
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Recruiting
AbbVie
Phase 2/3
490
London, Manchester
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
London, Cardiff, Nottingham
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton
2025-12-09
Recruiting
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
AstraZeneca
Phase 1
24
Cambridge, London
2025-12-09
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
London
2025-12-08
Active, closed
AstraZeneca
Phase 2
222
Dundee, Liverpool, London
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Birmingham, Glasgow, Greater London, Leeds, London, Manchester
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
London, Manchester
2025-12-04
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Cambridge, Cottingham, Edinburgh, Greater London, Guildford, London, Metropolitan Borough of Wirral, Northwood
2025-12-03
Recruiting
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Recruiting
GlaxoSmithKline
Phase 1
83
Leicester, London, Sutton
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield
2025-12-03
Recruiting
Sanofi
Phase 2
37
Newcastle upon Tyne, London
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
London
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-12-02
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton
2025-11-30
Recruiting
Amgen
Phase 3
750
London, Sutton
2025-11-28
Active, closed
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
24
London
2025-11-28
Recruiting
Hoffmann-La Roche
Phase 3
250
Leicester, Gloucester, London
2025-11-27
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
75
Birmingham, Cambridge, Leicester, London, Manchester
2025-11-26
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Lincoln, London, Southampton, Sutton
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Dundee, Exeter, London, Newcastle, Oxford, Plymouth,Devon
2025-11-24
Recruiting
AstraZeneca
Phase 4
56
Harefield, London, Manchester
2025-11-24
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Active, closed
Bayer
Phase 2
60
Exeter, London, Sheffield, Sunderland
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
600
Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Recruiting
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
iOnctura
Phase 1/2
26
Boston, Belfast, London
2025-11-17
Active, closed
Pfizer
Observational
250
London
2025-11-15
Recruiting
UCB Biopharma SRL
Phase 3
320
London, Salford
2025-11-14
Recruiting
Incyte Corporation
Phase 3
250
London, Sheffield, Walsall
2025-11-13
Recruiting
Prima Mente
Observational
1,000
London, Newport, Bradford, Bridgend, Llanelli, Newcastle upon Tyne, Penarth, Reading
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
Incyte Corporation
Phase 2
160
London, Manchester Greater
2025-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Bristol, Yate, London, Corby
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Brighton, Romford, Coventry, Glasgow, Leeds, London, Nottingham
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Liverpool, Dorchester, Wolverhampton, London, Sunderland
2025-11-10
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Birmingham, Cambridge, London
2025-11-10
Active, closed
Pfizer
Phase 2
42
London
2025-11-10
Recruiting
AstraZeneca
Phase 1
40
London
2025-11-10
Recruiting
Annexin Pharmaceuticals AB
Phase 2
12
London
2025-11-07
Recruiting
Sanofi
Phase 2
208
London, Leeds
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Glasgow, London, Sulton, Surrey
2025-11-05
Recruiting
AbbVie
Phase 3
561
Gloucester, London, Liverpool, Bristol, Newcastle upon Tyne, Sunderland
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
330
Liskeard, Newquay, Torquay, Bushey, London
2025-11-05
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
40
London
2025-11-04
Recruiting
AstraZeneca
Phase 1
72
London, Manchester
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Recruiting
Takeda
Observational
10
Dorchester, Birmingham, London, Wrexham
2025-11-03
Recruiting
Eli Lilly and Company
Phase 3
1,205
London, Plymouth, Stoke-on-Trent, Swansea, West End
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
2025-10-31
Recruiting
A Study With CIT-013 in HS Patients
NCT06993233Hidradenitis Suppurativa (HS)
DrugsCIT-013 medium·CIT-013
Citryll BV
Phase 2
96
Cardiff, Chester, London
2025-10-31
Recruiting
BioNTech SE
Phase 3
558
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl
2025-10-30
Recruiting
Shionogi
Phase 2
45
Birmingham, London, Newcastle upon Tyne, Salford
2025-10-30
Active, closed
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
400
London
2025-10-29
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Brighton, Newcastle upon Tyne, Liverpool, London
2025-10-28
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Gloucester, London, Newcastle, Southampton, Sunderland, York, Belfast
2025-10-28
Recruiting
Beam Therapeutics Inc.
Phase 1
30
London
2025-10-27
Recruiting
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
Endowave Ltd.
Not applicable
43
London
2025-10-24
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 1/2
6
London
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Eastbourne, London, Londonderry, Nottingham
2025-10-24
Recruiting
Novo Nordisk A/S
Phase 1
36
London
2025-10-23
Recruiting
Novo Nordisk A/S
Phase 1
30
Birmingham, London, Sheffield
2025-10-23
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Birmingham, London, Metropolitan Borough of Wirral
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bath, Leeds, London, Manchester, Torquay
2025-10-22
Recruiting
Lantheus Germany GmbH
Phase 1
15
London
2025-10-21
Recruiting
Intervene, Inc.
Not applicable
30
London
2025-10-18
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
London, Oxford
2025-10-17
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Doncaster, Eastbourne, Glasgow, Hayle, Hounslow, London, Newquay
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Recruiting
Vega Therapeutics, Inc
Phase 3
60
London
2025-10-15
Not yet open
Assessing Patient Preference for Infusion Systems
NCT07189013Primary Immunodeficiencies (PID), Secondary Immunodeficiencies (SID)
KORU Medical Systems, Inc.
Not applicable
52
London
2025-10-15
Recruiting
Alnylam Pharmaceuticals
Phase 1
50
Glasgow, London, Sheffield, Southampton
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
Nurix Therapeutics, Inc.
Phase 2
100
Headington, London, Manchester
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Sutton, London
2025-10-15
Recruiting
Gesynta Pharma AB
Phase 2
190
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 2
60
London, Oxford
2025-10-13
Recruiting
Sanofi
Phase 1/2
104
London
2025-10-09
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Liverpool, London
2025-10-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Harlow, Leeds, London
2025-10-08
Recruiting
Bristol-Myers Squibb
Observational
223
Oxford, Bath, Wolverhampton, London
2025-10-08
Recruiting
Celgene
Phase 1/2
62
London, Manchester
2025-10-07
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
London, Glasgow, Oxford
2025-10-06
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
2025-10-03
Recruiting
Pfizer
Phase 2/3
982
Cambridge, London, Edinburgh, Liverpool
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool
2025-10-02
Recruiting
Myota GmbH
Not applicable
156
London
2025-10-02
Recruiting
AstraZeneca
Phase 1/2
283
Cambridge, London, Plymouth, Sutton
2025-10-01
Recruiting
AI-Driven Early Detection of Skin Cancer
NCT07144306Skin Cancer Melanoma
Nuvana Healthcare LTD
Observational
100
London
2025-10-01
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport
2025-10-01
Recruiting
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Bristol, Cambridge, Frimley, Hampstead, London, Plymouth
2025-10-01
Recruiting
Sanofi
Phase 3
980
Cottingham, Cambridge, London, Norwich, Rochdale
2025-10-01
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Glasgow, London, Sheffield
2025-09-30
Recruiting
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield
2025-09-29
Recruiting
Genentech, Inc.
Phase 2
224
London, Liverpool, Oxford, Cambridge
2025-09-29
Recruiting
Pfizer
Phase 3
680
London, Manchester
2025-09-29
Recruiting
iSTAR Medical
Not applicable
60
Colchester, Grimsby, Liverpool, London
2025-09-29
Recruiting
AAVantgarde Bio Srl
Phase 1/2
75
London
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Manchester
2025-09-28
Recruiting
Sanofi
Phase 3
124
London, Norwich, Oxford
2025-09-26
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
London
2025-09-26
Recruiting
AstraZeneca
Phase 1/2
91
London, Newcastle upon Tyne
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
London, Birmingham, Hull
2025-09-23
Recruiting
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
30
Cambridge, Leicester, London, Salford
2025-09-19
Recruiting
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Bradford, Wakefield, Leeds, London
2025-09-18
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Recruiting
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 4
50
Cambridge, London, Manchester
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Nottingham, London, Salford
2025-09-16
Recruiting
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Antrim, Bath, Birmingham, Leeds, London, Londonderry, Luton, Preston
2025-09-13
By invitation
Lupin Ltd.
Phase 3
176
London
2025-09-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Truro, London, Belfast, Manchester, Nottingham
2025-09-11
Recruiting
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Cottingham, London, Southampton, Stevenage, Surrey
2025-09-10
Recruiting
Intuitive Surgical
Observational
1,200
London, Manchester
2025-09-09
Recruiting
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne
2025-09-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
Ocus Innovation Ireland Limited
Phase 3
234
Belfast, Birmingham, London
2025-09-01
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Oxford
2025-08-30
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Guildford, Cambridge, Cardiff, London, Southampton
2025-08-28
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 3
172
Birmingham, London, Manchester, Cottingham
2025-08-27
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Nottingham, Swindon, Truro
2025-08-26
Recruiting
Pfizer
Phase 3
6,000
Bristol, London, Manchester, Truro, Southampton, Oxford, Shropshire, Leeds
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Salford, Leeds, London
2025-08-22
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
London, Manchester
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
London
2025-08-19
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
DrugAZD0120
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
London
2025-08-18
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
London, Newcastle upon Tyne
2025-08-18
Recruiting
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
GlaxoSmithKline
Phase 2
220
Birmingham, Bristol, London
2025-08-14
Recruiting
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503Healthy Adult Participants
ADARx Pharmaceuticals, Inc.
Phase 1
44
London
2025-08-12
Recruiting
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
Sanofi
Phase 3
192
London
2025-08-12
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
London, Manchester, Oxford, Bath, Sheffield
2025-08-11
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
GlaxoSmithKline
Phase 3
420
London, Portsmouth, Truro
2025-08-11
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
6
Leeds, London
2025-08-11
Recruiting
Hvivo
Observational
250
London
2025-08-08
Recruiting
AstraZeneca
Phase 3
250
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
Sanofi
Phase 3
723
Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading
2025-08-06
Active, closed
Vir Biotechnology, Inc.
Phase 2
100
London, Manchester, Nottingham
2025-08-05
Active, closed
Ensoma
Phase 1/2
15
London
2025-08-05
Recruiting
Autolus Limited
Phase 1
18
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Recruiting
AstraZeneca
Phase 3
800
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
2025-08-01
Active, closed
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive
DrugsBinimetinib·Encorafenib
Pierre Fabre Ltd
Observational
50
Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton
2025-07-31
Recruiting
Amgen
Phase 1
434
London, Sutton
2025-07-31
Recruiting
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
NCT07127172Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
Neuralink Corp
Not applicable
7
London, Newcastle upon Tyne
2025-07-31
Active, closed
Pfizer
Phase 3
208
Brighton, London
2025-07-31
Recruiting
Salutare Group Ltd.
Not applicable
40
London
2025-07-31
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
BioMarin Pharmaceutical
Phase 2
60
London
2025-07-30
Active, closed
Vir Biotechnology, Inc.
Phase 3
150
London, Manchester, Nottingham
2025-07-30
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
Gloucester, London, Southampton, Sunderland, Belfast, Frimley, Manchester
2025-07-30
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
London
2025-07-29
Active, closed
Boehringer Ingelheim
Phase 1
16
Edinburgh, London
2025-07-29
Recruiting
CSL Behring
Phase 3
20
London, Oxford
2025-07-28
Recruiting
Celgene
Phase 3
400
Cringleford, Canterbury, London, Manchester
2025-07-28
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
London, Southampton
2025-07-25
Recruiting
Pharmazz, Inc.
Phase 3
514
Bury, London, Southampton, Wolverhampton, Harrow, Newcastle, Stoke-on-Trent
2025-07-24
Recruiting
Pfizer
Phase 3
714
Truro, Sheffield, Southampton, Northwood, London, Taunton, Ipswich, Manchester
2025-07-23
Recruiting
4D Molecular Therapeutics
Phase 3
480
Bradford, London, Sunderland
2025-07-22
Recruiting
CSL Behring
Observational
200
Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
London, Leicester, Manchester
2025-07-21
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Recruiting
BioNTech SE
Phase 1/2
482
London, Manchester, Sutton
2025-07-18
Active, closed
A Study to Assess THN391 in Subjects With Alzheimer's Disease
NCT06814730Alzheimer Disease, Early Onset
DrugTHN391
Therini Bio, Inc.
Phase 1
19
Edinburgh, London
2025-07-17
Recruiting
AstraZeneca
Phase 2
100
Bristol, Dundee, Headington, London, Norwich
2025-07-17
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham
2025-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Birmingham, London, Oxford, Coventry, Cardiff, Manchester
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Active, closed
Aligos Therapeutics
Phase 2
200
Glasgow, Leicester, London
2025-07-15
Recruiting
Apreo Health, Inc.
Not applicable
250
London
2025-07-15
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
London, Metropolitan Borough of Wirral, Crownhill, Plymouth, Liverpool
2025-07-14
Recruiting
Creo Medical Limited
Observational
18
London
2025-07-14
Recruiting
Galderma R&D
Observational
1,000
London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds
2025-07-14
Active, closed
ViiV Healthcare
Phase 1
107
London
2025-07-10
Recruiting
CSL Behring
Phase 2
70
Liverpool, London
2025-07-10
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Leeds, London, Manchester
2025-07-09
Active, closed
Sanofi
Phase 2
105
Northwich, Bury, London
2025-07-07
Recruiting
Radiation Free Study
NCT06549348Aortic Aneurysm
Philips Clinical & Medical Affairs Global
Not applicable
182
London
2025-07-03
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Cambridge, London
2025-07-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bellshill, Birmingham, Cardiff, London, Manchester
2025-07-02
Not yet open
Santersus AG
Not applicable
73
Birmingham, Edinburgh, Liverpool, London
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Oxford, Sutton, Windsor, London
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
London, Dundee, Huddersfield, Colchester, Orpington, Nottingham, Blackpool, Leicester
2025-06-30
Recruiting
Ipsen
Phase 2
132
Exeter, Fazakerley, London, Luton
2025-06-30
Recruiting
Azafaros B.V.
Phase 3
147
London, Manchester
2025-06-30
Recruiting
Azafaros B.V.
Phase 3
72
London, Manchester
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-30
Recruiting
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Active, closed
Immunovant Sciences GmbH
Phase 2
180
Cambridge, Liverpool, London, Swindon, Truro
2025-06-30
Active, closed
Mundipharma Research Limited
Phase 2
60
Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester
2025-06-30
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2025-06-30
Recruiting
Hoffmann-La Roche
Phase 3
75
London, Manchester
2025-06-27
Recruiting
AstraZeneca
Phase 2
987
Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-27
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
London
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Bristol, Dundee, Exeter, London
2025-06-26
Recruiting
MowOot and Trans-anal Irrigation fOr coNstipation
NCT06833684Constipation Chronic Idiopathic
usMIMA S.L.
Not applicable
40
London
2025-06-25
Active, closed
DBV Technologies
Phase 3
480
Glasgow, Leicester, London, Manchester, Sheffield, Southampton
2025-06-24
Recruiting
Ethris GmbH
Phase 2
50
London, Manchester
2025-06-24
Recruiting
Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)
NCT06885931Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
Amber Therapeutics Ltd
Not applicable
86
Bristol, London
2025-06-24
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Sheffield, Leeds, London, Swansea
2025-06-23
Recruiting
Enterra Medical, Inc.
Not applicable
148
London, Manchester
2025-06-23
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
Bladder EpiCheck European Haematuria Study
NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Nucleix Ltd.
Observational
800
Dunfermline, Cambridge, Edinburgh, London, Surrey Quays
2025-06-20
By invitation
BioMarin Pharmaceutical
Phase 3
140
London
2025-06-20
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Cornwell, London, Merthyr Tydfil, Salford, Surrey
2025-06-19
Recruiting
Pfizer
Phase 2
620
Dundee, London, Norwich, Chichester, Belfast, High Wycombe
2025-06-19
Recruiting
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Active, closed
Incyte Corporation
Phase 3
159
Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall
2025-06-17
Active, closed
AbbVie
Phase 3
573
London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport
2025-06-17
Recruiting
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235Primary Hyperoxaluria Type 1 (PH1)
Arbor Biotechnologies
Phase 1/2
23
Birmingham, London
2025-06-16
Recruiting
Relay Therapeutics, Inc.
Phase 2
277
London
2025-06-13
Recruiting
BeOne Medicines
Phase 3
630
Bournemouth, Headington, Leeds, London, Metropolitan Borough of Wirral, Newcastle upon Tyne, Truro
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
London, Newcastle upon Tyne, Sheffield
2025-06-10
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
London, Oxford
2025-06-10
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Dudley, London
2025-06-09
Recruiting
Nova Laboratories Limited
Observational
180
Basildon, Cardiff, London, Manchester, Oxford
2025-06-09
Active, closed
Biogen
Phase 3
255
London, Oxford, Sheffield
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 2
300
Camberley, Gloucester, Harrow, Liverpool, London, Newcastle upon Tyne, Sunderland, Westcliff-on-Sea
2025-06-05
Recruiting
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
NCT06797999Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Adcendo ApS
Phase 1/2
270
London
2025-06-05
Recruiting
GlaxoSmithKline
Phase 2
80
Boston, London, Manchester
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth
2025-06-04
Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
DrugSepofarsen
Laboratoires Thea
Phase 3
32
London
2025-06-04
Recruiting
Stoke Therapeutics, Inc
Phase 3
170
Glasgow, London, Sheffield
2025-06-04
Active, closed
Incyte Corporation
Phase 3
9
Cardiff, Glasgow, Leeds, Leicester, London
2025-06-04
Recruiting
Sanofi
Phase 2
99
Bury, Cambridge, London
2025-06-03
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Glasgow, London
2025-05-30
Recruiting
Neurocrine Biosciences
Phase 3
200
London, Salford, Sheffield, Southampton
2025-05-30
Rows per page Showing 1–500 of 2015
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,015 of those studies with a site in London.

How many clinical trials are recruiting in London?

976 of the 2,015 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 28 have not yet opened recruitment, 950 are active but closed to new participants, and 61 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 2,015 studies
PhaseStudiesRecruitingShare
Phase 386936843.1%
Phase 239117619.4%
Phase 1/220313210.1%
Observational1951169.7%
Phase 1152797.5%
Not applicable101475%
Phase 2/381474%
Phase 422101.1%
Early Phase 1110%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
AstraZeneca13766
Merck Sharp & Dohme LLC9848
Hoffmann-La Roche8127
Novartis Pharmaceuticals7233
Janssen Research & Development, LLC7127
AbbVie5117
Eli Lilly and Company4527
Pfizer4319
Bristol-Myers Squibb4024
Sanofi3814
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.